We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 15, 2021

Bone-Protective Effects of Everolimus for Premenopausal HR+/HER2− Metastatic Breast Cancer

International Journal of Cancer

 

Additional Info

International Journal of Cancer
Final Results of the Randomized Phase 2 LEO Trial and Bone Protective Effects of Everolimus for Premenopausal Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Int. J. Cancer 2021 Apr 27;[EPub Ahead of Print], H Jeong, JH Jeong, JE Kim, JH Ahn, KH Jung, SJ Koh, J Cheon, J Sohn, GM Kim, KS Lee, SH Sim, IH Park, SB Kim

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading